Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 59 for:    MLN8237
Previous Study | Return to List | Next Study

MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02444884
Recruitment Status : Completed
First Posted : May 15, 2015
Last Update Posted : February 9, 2016
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group

Brief Summary:

RATIONALE: MLN8237 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I/II trial is studying the side effects and best dose of MLN8237 and to see how well it works in treating young patients with relapsed or refractory solid tumors


Condition or disease Intervention/treatment Phase
Unspecified Childhood Solid Tumor, Excluding CNS Neuroblastoma Drug: MLN8237 Phase 1

Detailed Description:

1.1 Primary Aims 1.1.1 To estimate the maximum tolerated dose (MTD) and recommended Phase II dose of MLN8237 administered orally once daily for 7 days every 21 days to children with refractory solid tumors. 1.1.2 To estimate the maximum tolerated dose (MTD) and recommended Phase II dose of MLN8237 administered orally twice daily for 7 days every 21 days to children with refractory solid tumors. 1.1.3 To define and describe the toxicities of MLN8237 administered on this schedule.

1.1.4 To characterize the pharmacokinetics of MLN8237 in children with refractory cancer.

1.2 Secondary Aims 1.2.1 To preliminarily define the antitumor activity of MLN8237 within the confines of a Phase I study. 1.2.2 To obtain initial Phase II efficacy data on the anti-tumor activity of MLN8237 in children with relapsed-refractory neuroblastoma using the once daily dosing schedule. 1.2.3 To explore the relationship between polymorphic variations in the UDPglucuronyltransferase gene UGT1A1 and exposure to MLN8237.

1.2.4 To assess two common polymorphic variants in the Aurora A kinase gene (Phe31Ile and Val57Ile) thought to potentially influence tumorigenesis. 1.2.5 To preliminarily examine the relationsh


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors
Study Start Date : September 2008
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Stratum A1
Establish MTD in patients with solid tumors MLN8237 orally, once daily on Days 1-7
Drug: MLN8237
Other Name: Alisertib

Experimental: Stratum A2
MTD determined in Stratum A1in patients with solid tumors MLN8237 orally, twice daily on Days 1-7
Drug: MLN8237
Other Name: Alisertib

Experimental: Stratum B
Expand MTD in patients with neuroblastoma MLN8237 orally, once daily on Days 1-7
Drug: MLN8237
Other Name: Alisertib




Primary Outcome Measures :
  1. Determine maximum tolerated dose and RP2D administered once daily on Days 1-7 [ Time Frame: Up to 21 days (1st cycle) of protocol therapy ]
  2. Determine maximum tolerated dose and RP2D administered po BID on Days 1-7 [ Time Frame: Up to 21 days (1st cycle) of protocol therapy ]
  3. Adverse events as assessed by (CTCAE) version 4.0 [ Time Frame: Every 21 days (each cycle) of protocol therapy for up to 35 cycles [up to 105 weeks] ]
    DLT will be defined as possibly, probably or definitely attributable to MLN8237. The DLT observation period for the purposes of dose-escalation will be the first cycle of therapy

  4. PK Profile: MLN8237 concentrations in plasma samples [ Time Frame: 30 min after the first dose, and at 1,2, 3, 4, 6-8, 24 hours, Day 4 and 7 in Cycle 1 ]
    single-dose AUC, trough estimation, t½ of accumulation



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Months to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis: Patients must have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of CSF or serum tumor markers including alpha-fetaprotein or beta-HCG.
  • Performance Level: Karnofsky >/= 50% for patients > 16 years of age and Lansky

    >/= 50 for patients </=16 years of age

  • Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
  • Adequate Bone Marrow Function Defined as:

    a. For patients with solid tumors:

  • Peripheral absolute neutrophil count (ANC) >/= 1000/microLiter
  • Platelet count >/= 100,000/microLiter (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment)
  • Hemoglobin >/= 8.0 g/dL (may receive RBC transfusions)
  • Creatinine clearance or radioisotope GFR >/= 70ml/min/1.73 m2
  • Bilirubin (sum of conjugated + unconjugated) </= 1.5 x upper limit of normal (ULN) for age, and
  • SGPT (ALT) </= 5.0 x ULN for age (≤ 225 U/L). For the purpose of this study, the ULN for SGPT is 45 U/L.
  • Serum albumin >/= 2 g/dL.

Exclusion Criteria:

  • Pregnant or breast-feeding women will not be entered on this study
  • Growth factors that support platelet or white cell number or function must not have been administered within the 7 days prior to enrollment.
  • Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the prior 7 days are not eligible.
  • Patients who are currently receiving another investigational drug are not eligible.
  • Patients who are currently receiving other anticancer agents, digoxin, cyclosporine, tacrolimus or sirolimus, use of daily benzodiazepines are not eligible
  • Patients who have an uncontrolled infection are not eligible.

Layout table for additonal information
Responsible Party: Children's Oncology Group
ClinicalTrials.gov Identifier: NCT02444884     History of Changes
Other Study ID Numbers: ADVL0812
First Posted: May 15, 2015    Key Record Dates
Last Update Posted: February 9, 2016
Last Verified: February 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroblastoma
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue